Skip to Main content Skip to Navigation
Journal articles

CD200: a putative therapeutic target in cancer.

Abstract : CD200 was recently described as a new prognosis factor in multiple myeloma and acute myeloid leukemia. CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. We investigated the expression of CD200 in cancer using publicly available gene expression data. CD200 gene expression in normal or malignant human tissues or cell lines was obtained from the Oncomine Cancer Microarray database, Amazonia database and the ITTACA database. We found significant overexpression of CD200 in renal carcinoma, head and neck carcinoma, testicular cancer, malignant mesothelioma, colon carcinoma, MGUS/smoldering myeloma, and in chronic lymphocytic leukemia compared to their normal cells or their tissue counterparts. Moreover, we show that CD200 expression is associated with tumor progression in various cancers. Taken together, these data suggest that CD200 is a potential therapeutic target and prognostic factor for a large array of malignancies.
Document type :
Journal articles
Complete list of metadata
Contributor : Monique Frei Connect in order to contact the contributor
Submitted on : Monday, December 10, 2007 - 12:30:04 PM
Last modification on : Friday, September 9, 2022 - 10:20:08 AM
Long-term archiving on: : Monday, April 12, 2010 - 6:45:11 AM




Jérôme Moreaux, Jean-Luc Veyrune, Thierry Rème, John de Vos, Bernard Klein. CD200: a putative therapeutic target in cancer.. Biochemical and Biophysical Research Communications, Elsevier, 2008, 366 (1), pp.117-22. ⟨10.1016/j.bbrc.2007.11.103⟩. ⟨inserm-00195258⟩



Record views


Files downloads